Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

The observational MCL-004 study evaluated outcomes in patients with relapsed/refractory mantle cell lymphoma who received lenalidomide-based therapy after ibrutinib failure or intolerance.

Source: Journal of Hematology and Oncology - November 2, 2017 Category: Hematology Authors: Michael Wang, Stephen J. Schuster, Tycel Phillips, Izidore S. Lossos, Andre Goy, Simon Rule, Mehdi Hamadani, Nilanjan Ghosh, Craig B. Reeder, Evelyn Barnett, Marie-Laure Casadebaig Bravo and Peter Martin Tags: Research Source Type: research